Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study.
暂无分享,去创建一个
F. De Keyzer | F. Amant | R. Vanslembrouck | P. Moerman | R. Dresen | S. Fieuws | V. Vandecaveye | K. Leunen | I. Vergote | K. Op de beeck | K. Michielsen
[1] M. Forsting,et al. Comparison of 18F–FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[2] L. Massuger,et al. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. , 2015, Gynecologic oncology.
[3] K. Sugimura,et al. Role of Diffusion Weighted Imaging and Contrast-Enhanced MRI in the Evaluation of Intrapelvic Recurrence of Gynecological Malignant Tumor , 2015, PloS one.
[4] Michael Forsting,et al. Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone , 2014, Investigative radiology.
[5] S. Dymarkowski,et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT , 2014, European Radiology.
[6] L. Massuger,et al. External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer , 2013, British Journal of Cancer.
[7] M. Espada,et al. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma , 2013, European Radiology.
[8] S. Derchain,et al. Staging recurrent ovarian cancer with 18FDG PET/CT , 2012, Oncology letters.
[9] D. Lorusso,et al. The Role of Secondary Surgery in Recurrent Ovarian Cancer , 2012, International journal of surgical oncology.
[10] G. Ferron,et al. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[11] R. Rouzier,et al. Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. , 2011, Radiology.
[12] G. Beets,et al. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer , 2011, European Radiology.
[13] A. Reuss,et al. Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO , 2010, International Journal of Gynecologic Cancer.
[14] Stan B. Kaye,et al. Imaging ovarian cancer and peritoneal metastases—current and emerging techniques , 2010, Nature Reviews Clinical Oncology.
[15] H. Hricak,et al. Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.
[16] R. Low,et al. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. , 2009, AJR. American journal of roentgenology.
[17] Gang Huang,et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. , 2009, European journal of radiology.
[18] Nina Ditsch,et al. PET-CT in recurrent ovarian cancer: impact on treatment planning. , 2008, Anticancer research.
[19] R. Forstner. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI , 2007, European Radiology.
[20] D. Collins,et al. Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.
[21] Sandra Nuyts,et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. , 2007, International journal of radiation oncology, biology, physics.
[22] J. Huober,et al. Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial , 2006, Annals of Surgical Oncology.
[23] B. Duggan,et al. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. , 2005, Radiology.
[24] E. Venkatraman,et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. , 2004, American journal of obstetrics and gynecology.
[25] L. Balestreri,et al. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. , 2002, La Radiologia medica.
[26] H. Imhof,et al. CT and MR Accuracy in the Detection of Tumor Recurrence in Patients Treated for Ovarian Cancer , 1993, Journal of computer assisted tomography.
[27] I. Vergote,et al. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? , 2013, Gynecologic oncology.
[28] C. Tropé,et al. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] S. Fujii,et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging , 2007, European Radiology.
[30] G. V. von Schulthess,et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma , 2000, European Radiology.